Syndrome of Inappropriate Secretion of Antidiuretic Hormone Due to Olanzapine Use

Olanzapin Kullanımına Bağlı Gelişen Uygunsuz Antidiüretik Hormon Sendromu

Gülay Kır[1], Esra Gözügül[1], Ayşe Düşünür[2], Cengiz Yumru[1]

[1]Clinic of Anesthesiology ve Reanimation, Gaziosmanpaşa Taksim Training and Research Hospital, İstanbul, Turkey
[2]Beyoğlu Public Hospitals Body General Secretarial, Medical Services Head Office, İstanbul, Turkey

Cite this article as: Kır G, Gözügül E, Düşünür A, Yumru C. Syndrome of Inappropriate Secretion of Antidiuretic Hormone Due to Olanzapine Use. JAREM 2017; 7: 158-60.

ABSTRACT

Hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone (SIADH), which is characterized by the sustained release of antidiuretic hormone (ADH) from the posterior pituitary gland, is a less-known but life-threatening complication of treatment with antipsychotic medications. We report a patient who was using olanzapine due to the diagnosis of schizophrenia and presented with status epilepticus. The patient's medical history and biochemical blood and urine test results were suggestive of SIADH and revealed that hyponatremia was secondary to SIADH, induced by olanzapine use. The patient was treated succesfully with olanzapine discontinuation, fluid restriction, and hypertonic/normal saline infusion. The possible adverse effects of olanzapine on sodium-water balance should always be kept in mind while prescribing it, and we suggest that clinicians should closely monitor electrolytes, particularly sodium, in patients on atypical antipsychotic medications such as olanzapine.

Keywords: Olanzapine, hyponatremia, syndrome of inappropriate secretion of antidiuretic hormone, antipsychotic medications, schizophrenia

ÖZ

Posterior hipofizden antidiüretik hormonun (ADH) sürekli salınımı ile karakterize uygunsuz ADH sendromu sonucu gelişen hiponatremi, antipsikotik ilaç tedavisinin az bilinen ama yaşamı tehdit eden bir komplikasyonudur. Bu makalede status epilepticus tablosunda başvuran, şizofreni tanısı ile olanzapin kullanan hastayı sunduk. Hastanın uygunsuz ADH sendromunu işaret eden medikal öyküsü, biyokimyasal kan ve idrar sonuçları, hiponatreminin olanzapin kullanımına bağlı gelişen uygunsuz ADH sendromundan kaynaklandığını ortaya koymuştur. Hasta, olanzapininin kesilmesi, sıvı kısıtlaması ve hipertonik/normal salin replasmanı ile başarıyla tedavi edilmiştir. Olanzapin tedavisi planlandığında, su-sodyum dengesi üzerine olası yan etkilerinin akılda tutulmasının, olanzapin gibi atipik antipsikotik ilaç kullanan hastaların başta sodyum olmak üzere elektrolitlerinin yakından takip edilmesinin önemini tekrar vurgulamak isteriz.

Anahtar Kelimeler: Olanzapin, hiponatremi, uygunsuz antidiüretik hormon sendromu, antipsikotik ajanlar, şizofreni

INTRODUCTION

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is characterized by the sustained release of antidiuretic hormone (ADH) in the absence of either osmotic or non-osmotic stimuli or by enhanced renal action of ADH. It is characterized by dilutional hyponatremia (<135 mmol/l), increased urine sodium levels (>20 mmol/l), inappropriately elevated urine osmolality (>100 mOsm/kg) relative to plasma osmolality (<280 mOsm/kg), and expanded extracellular volume in euvolemic patients taking no diuretics, with normal cardiac, hepatic, renal, adrenal, and thyroid functions. SIADH can be induced by various conditions, including malignancies (carcinomas: bronchogenic, pancreatic, prostatic, thymoma, lymphoma, mesothelioma), pulmonary diseases (asthma, pneumonia, tuberculosis, empyema), central nervous system disorders (meningitidis, ensephalitis, cerebrovascular accidents, subarachnoidal hemorrhage, head trauma), and numerous drugs (vasopressin, desmopressin, oxytocin, antidepressants, antipsychotics, carbamazepine) (1).

Olanzapine is an atypical antipsychotic agent indicated for the first-line treatment of schizophrenia and moderate-to-severe manic episodes in bipolar disorder. In psychiatric patients on antipsychotic medications in whom psychogenic polydipsia is excluded, hyponatremia, a life-threatening complication, occurs secondary to SIADH. Similar to other antipsychothics such as chlorpromazine, amisulpride, fluphenazine, haloperidol, trifluoperazine, risperidone, and clozapine, olanzapine causes hyponatremia by stimulating inappropriate release of ADH. In a systemic review by Meulendijks et al. (2) it was concluded that antipsychotic drug-induced hyponatremia does not seem to be dose dependent or associated with age or gender (3-5). We report a patient presenting with life-threatening severe hyponatremia caused by SIADH, induced by olanzapine treatment; this has been rarely observed in the literature, with only a few relevant reports.

This case report was presented as an electronic poster in 18th National Intensive Care Congress (6-10 April 2016, Antalya, Turkey).
Bu olgu sunumu 18. Ulusal Yoğun Bakım Kongresi'nde elektronik poster olarak sunulmuştur (6-10 Nisan 2016, Antalya, Türkiye).

Address for Correspondence / Yazışma Adresi: Gülay Kır
E-mail: drglycnr@yahoo.com

Received Date / Geliş Tarihi: 25.07.2016 **Accepted Date / Kabul Tarihi:** 12.10.2016
Çevrimiçi Yayın Tarihi / Available Online Date: 23.01.2017

DOI: 10.5152/jarem.2016.1252

CASE PRESENTATION

A 49-year-old female using 40 mg olanzapine daily for the past 6 years due to the diagnosis of chronic schizophrenia was brought to the emergency room in a postictal confusional state following a witnessed episode of generalized tonic-clonic seizure and vomiting. There were no other chronic diseases, malignancies, concomitant medications, or compulsive drinking in her medical history. Shortly after admission, she had respiratory arrest, and she was therefore intubated and transferred to the intensive care unit (ICU).

Her hemodynamic parameters and oxygenation was found to be normal. No peripheral edema or hypovolemia findings such as tachycardia, postural blood pressure changes, dry mucous membranes, or poor skin turgor were observed. Her phsycial examination was unremarkable, with normal electrocardiography and echocardiography findings. Her cranial and abdominal CT scans did not reveal any abnormal findings; however, infiltration was observed in the right lung, suggesting the need for aspiration on chest CT scan. Her temperature was 36.4°C, and total blood count, renal functions, liver enzymes, and thyroid hormone levels were within the normal limits. Laboratory testings revealed the following: hyponatremia (Na: 114 mmol/l) with K: 3,48 mmol/l, Cl: 82 mmol/l, Ca: 82 mmol/l, serum osmolality: 238 mOsm/kg, urinary Na: 51 mmol/l, urinary osmolality: 274 mOsm/kg, and urine density: 1010. Seizures were attributed to severe hyponatremia, and the patient's medical history and all the clinical and laboratory findings mentioned above revealed that hyponatremia was secondary to SIADH, induced by olanzapine use.

Discontinuation of olanzapine, restriction of fluid intake, and treatment with hypertonic/normal saline resulted in the resolution of hyponatremia (6 h: 122 mmol/l, 12 h: 125 mmol/l, 24 h: 129 mmol/l, 36 h: 138 mmol/l). In addition, antibiotheraphy for suspicious aspiration pneumonia was initiated shortly after the admission to the ICU. She was extubated on day 2, with completely normal neurological examination. She did not experience any further convulsions. Along with oral antibiotheraphy and psychiatric suggestions, including follow-up visits, she was discharged at the end of day 4 with approval for the use of her results in this case report.

DISCUSSION

Hyponatremia is a more frequent dangerous adverse reaction of olanzapine treatment than thought previously. In the World Health Organization (WHO) global individual case safety report database system, olanzapine was the second most common antipsychotic associated with hyponatremia after risperidone (6).

Animal studies have suggested that the inhibitory effect of dopamine (D_2) on the release of ADH is blocked by D_2 receptor antagonists such as haloperidol and domperidone, and it has also been shown that ADH response to a hypertonic stimulus is potantiated by D_2 antagonists. Because olanzapine is a selective monoaminergic antagonist with high binding affinity to D_2, serotonin, muscarine, histamine, and adrenergic receptors, it causes SIADH by its antagonism to D_2 receptors (7, 8).

While consulting a psychiatric patient with hyponatremia symptoms, it is important to rule out psychogenic polydipsia, a clinical disorder that occurs in 6% to 20% of psychiatric patients and is characterized by hyponatremia, polydipsia, and polyuria, in differential diagnosis. The key differences are low urinary osmolality (<100 mOsm/kg) and low urinary sodium levels (10 mEq/L) in patients with psychogenic polydipsia who also have a history of excessive water consumption. Cerebral salt wasting (CSW), which has similar laboratory and clinical findings as SIADH, is also an important diagnosis to consider in hyponatremic patients. It presents as low serum osmolality, high urine osmolality, and a high urine sodium level, similar to SIADH, but with a fundamental difference: hypovolemic hyponatremia. High levels of natriuretic peptides and fractional excretion of uric acid may also help differentiate between CSW and SIAH, although the key difference is the volume status of the patient. In this case, euvolemic hyponatremia with high urinary osmolality and urinary sodium levels but low serum osmolality revealed that hyponatremia was secondary to SIADH, induced by olanzapine use.

CONCLUSION

The possible adverse effects of olanzapine on sodium-water balance should always be kept in mind while prescribing it, and we suggest that clinicians should closely monitor electrolytes, particularly sodium, in patients on atypical antipsychotic medications such as olanzapine. Patients and their family members should be informed about hyponatremia symptoms, and emphasis should also be laid on the importance of the early identification of hyponatremia.

Informed Consent: Written informed consent was obtained from patients' daughter who participated in this case.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - G.K.; Design - G.K.; Supervision - A.D., C.Y.; Resources - C.Y., A.D.; Materials - E.G.; Data Collection and/or Processing - E.G.; Analysis and/or Interpretation - A.D., G.K.; Literature Search - E.G.; Writing Manuscript - G.K.; Critical Review - C.Y., A.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Hasta Onamı: Yazılı hasta onamı bu olgu sunumuna katılan hastanın kızından alınmıştır.

Hakem Değerlendirmesi: Dış bağımsız.

Yazar Katkıları: Fikir - G.K.; Tasarım - G.K.; Denetleme - A.D., C.Y.; Kaynaklar - C.Y., A.D.; Malzemeler - E.G.; Veri Toplanması ve/veya İşlemesi - E.G.; Analiz ve/veya Yorum - A.D., G.K.; Literatür Taraması - E.G.; Yazıyı Yazan - G.K.; Eleştirel İnceleme - C.Y., A.D.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Finansal Destek: Yazarlar bu çalışma için finansal destek almadıklarını beyan etmişlerdir.

KAYNAKLAR

1. Ramos-Levi AM, Duran Rodriguez-Hervada A, Mendez-Bailon M, Marco-Martinez J. Drug-induced hyponatremia: an updated review. Minerva Endocrinol 2014; 39: 1-12.

2. Meulendijks D, Mannesse CK, Jansen PA, van Marum RJ, Egberts TC. Antipsychotic-induced hyponatremia: A systematic review of the published evidence. Drug Saf 2010; 33: 101-14.
3. Collins A, Anderson J. SIADH induced by two atypical antipsychotics. Int J Geriatr Psychiatry 2000; 15: 282-3.
4. Kiss A, Bundzikova J, Pirnik Z, Mikkelsen JD. Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry. J Neurosci Res 2010; 88: 677-85.
5. Dudeja SJ, McCormick M, Dudeja RK. Olanzapine induced hyponatremia. Ulster Med J 2010; 79: 104-5.
6. Mannese CK, van Puijenbroek EP, Jansen PA, van Marum RJ, Souverein PC, Egberts TC. Hyponatraemia as an adverse drug reaction of antipsychotic drugs: A case-control study in VigiBase. Drug Saf 2010; 33: 569-78.
7. Yamaguchi K, Hama H, Adachi C. Inhibitory role of periventricular dopaminergic mechanisms in hemorrhage-induced vasopressin secretion in conscious rats. Brain Res 1990; 513: 335-8.
8. Wells T, Forsling ML. Aminergic control of vasopressin secretion in the conscious rat. J Physiol Pharmacol 1992; 43: 59-64.